Long-Term Cardiac Monitoring After Embolic Stroke of Undetermined Source: Search Longer, Look Harder - The American Journal of Medicine
Oral anticoagulants vs antiplatelets in cryptogenic stroke with potential cardiac emboli: Meta-analysis - ScienceDirect
NAVIGATE ESUS design overview. | Download Scientific Diagram
NAVIGATE ESUS will Provide Significant Insights into How Best to Protect Patients with a Recent Embolic Stroke of Undetermined S
NAVIGATE ESUS | Canadian Stroke Prevention Intervention Network
Stroke Spotlight: Cryptogenic Stroke & Embolic Stroke of Undetermined Score - Practical Neurology
NAVIGATE ESUS | Canadian Stroke Prevention Intervention Network
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial | Stroke
Navigate ESUS - Research Studies - PHRI - Population Health Research Institute of Canada
NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin | tctmd.com
Catch-up-ESUS - follow-up in embolic stroke of undetermined source (ESUS) in a prospective, open-label, observational study: study protocol and initial baseline data | BMJ Open
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial - The Lancet Neurology
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial | Neuroscience Hub
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale | Stroke
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial - Journal of Stroke and Cerebrovascular Diseases
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials
NAVIGATE ESUS design overview. | Download Scientific Diagram
![PDF] Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5f622cce5807f5a01f069af6480c58e109ab9229/25-Figure1-1.png "PDF] Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial | Semantic Scholar")
PDF] Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial | Semantic Scholar
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial - The Lancet Neurology
Embolic Stroke of Undetermined Source: JACC Review Topic of the Week | Journal of the American College of Cardiology
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source | NEJM
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial | Neuroscience Hub
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source | NEJM
Diagnosis and Treatment for embolic stroke of undetermined source: Consensus statement from the Taiwan stroke society and Taiwan society of cardiology - ScienceDirect
Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study | Neuroscience Hub
NAVIGATE ESUS: Trial result shows that rivaroxaban does not prevent recurrent cryptogenic stroke more than aspirin - NeuroNews International
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial - Journal of Stroke and
Main Results
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial - Robert G Hart, Mukul Sharma, Hardi Mundl, Ashkan Shoamanesh, Scott E
